Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 32

1.

Co-existence of IL7R high and SH2B3 low expression distinguishes a novel high-risk acute lymphoblastic leukemia with Ikaros dysfunction.

Ge Z, Gu Y, Xiao L, Han Q, Li J, Chen B, Yu J, Kawasawa YI, Payne KJ, Dovat S, Song C.

Oncotarget. 2016 Jul 19;7(29):46014-46027. doi: 10.18632/oncotarget.10014.

2.

LNK/SH2B3 regulates IL-7 receptor signaling in normal and malignant B-progenitors.

Cheng Y, Chikwava K, Wu C, Zhang H, Bhagat A, Pei D, Choi JK, Tong W.

J Clin Invest. 2016 Apr 1;126(4):1267-81. doi: 10.1172/JCI81468. Epub 2016 Mar 14.

3.

The role of small adaptor proteins in the control of oncogenic signalingr driven by tyrosine kinases in human cancer.

Naudin C, Chevalier C, Roche S.

Oncotarget. 2016 Mar 8;7(10):11033-55. doi: 10.18632/oncotarget.6929. Review.

4.

MERIT40 deficiency expands hematopoietic stem cell pools by regulating thrombopoietin receptor signaling.

Rozenova K, Jiang J, Donaghy R, Aressy B, Greenberg RA, Tong W.

Blood. 2015 Mar 12;125(11):1730-8. doi: 10.1182/blood-2014-07-588145. Epub 2015 Jan 30.

5.

The contribution of natural selection to present-day susceptibility to chronic inflammatory and autoimmune disease.

Brinkworth JF, Barreiro LB.

Curr Opin Immunol. 2014 Dec;31:66-78. doi: 10.1016/j.coi.2014.09.008. Epub 2014 Oct 22. Review.

6.

The molecular regulation of Janus kinase (JAK) activation.

Babon JJ, Lucet IS, Murphy JM, Nicola NA, Varghese LN.

Biochem J. 2014 Aug 15;462(1):1-13. doi: 10.1042/BJ20140712. Review.

7.

12q24 locus association with type 1 diabetes: SH2B3 or ATXN2?

Auburger G, Gispert S, Lahut S, Omür O, Damrath E, Heck M, Başak N.

World J Diabetes. 2014 Jun 15;5(3):316-27. doi: 10.4239/wjd.v5.i3.316. Review.

8.

LNK (SH2B3): paradoxical effects in ovarian cancer.

Ding LW, Sun QY, Lin DC, Chien W, Hattori N, Dong XM, Gery S, Garg M, Doan NB, Said JW, Xiao JF, Yang H, Liu LZ, Meng X, Huang RY, Tang K, Koeffler HP.

Oncogene. 2015 Mar 12;34(11):1463-74. doi: 10.1038/onc.2014.34. Epub 2014 Apr 7.

9.

Nov/CCN3 regulates long-term repopulating activity of murine hematopoietic stem cells via integrin αvβ3.

Ishihara J, Umemoto T, Yamato M, Shiratsuchi Y, Takaki S, Petrich BG, Nakauchi H, Eto K, Kitamura T, Okano T.

Int J Hematol. 2014 Apr;99(4):393-406. doi: 10.1007/s12185-014-1534-x. Epub 2014 Feb 22.

10.

Lnk adaptor suppresses radiation resistance and radiation-induced B-cell malignancies by inhibiting IL-11 signaling.

Louria-Hayon I, Frelin C, Ruston J, Gish G, Jin J, Kofler MM, Lambert JP, Adissu HA, Milyavsky M, Herrington R, Minden MD, Dick JE, Gingras AC, Iscove NN, Pawson T.

Proc Natl Acad Sci U S A. 2013 Dec 17;110(51):20599-604. doi: 10.1073/pnas.1319665110. Epub 2013 Dec 2.

11.

Oncogenic Nras has bimodal effects on stem cells that sustainably increase competitiveness.

Li Q, Bohin N, Wen T, Ng V, Magee J, Chen SC, Shannon K, Morrison SJ.

Nature. 2013 Dec 5;504(7478):143-7. doi: 10.1038/nature12830. Epub 2013 Nov 27.

12.

Genetic loss of SH2B3 in acute lymphoblastic leukemia.

Perez-Garcia A, Ambesi-Impiombato A, Hadler M, Rigo I, LeDuc CA, Kelly K, Jalas C, Paietta E, Racevskis J, Rowe JM, Tallman MS, Paganin M, Basso G, Tong W, Chung WK, Ferrando AA.

Blood. 2013 Oct 3;122(14):2425-32. doi: 10.1182/blood-2013-05-500850. Epub 2013 Aug 1.

13.

When the Brakes are Lost: LNK Dysfunction in Mice, Men, and Myeloproliferative Neoplasms.

Oh ST.

Ther Adv Hematol. 2011 Feb;2(1):11-9. doi: 10.1177/2040620710393391.

14.

Adaptor protein Lnk binds to and inhibits normal and leukemic FLT3.

Lin DC, Yin T, Koren-Michowitz M, Ding LW, Gueller S, Gery S, Tabayashi T, Bergholz U, Kazi JU, Rönnstrand L, Stocking C, Koeffler HP.

Blood. 2012 Oct 18;120(16):3310-7. doi: 10.1182/blood-2011-10-388611. Epub 2012 Aug 31.

15.

Lnk deficiency partially mitigates hematopoietic stem cell aging.

Bersenev A, Rozenova K, Balcerek J, Jiang J, Wu C, Tong W.

Aging Cell. 2012 Dec;11(6):949-59. doi: 10.1111/j.1474-9726.2012.00862.x. Epub 2012 Aug 27.

16.

14-3-3 regulates the LNK/JAK2 pathway in mouse hematopoietic stem and progenitor cells.

Jiang J, Balcerek J, Rozenova K, Cheng Y, Bersenev A, Wu C, Song Y, Tong W.

J Clin Invest. 2012 Jun;122(6):2079-91. doi: 10.1172/JCI59719. Epub 2012 May 1.

17.

Integrin-αvβ3 regulates thrombopoietin-mediated maintenance of hematopoietic stem cells.

Umemoto T, Yamato M, Ishihara J, Shiratsuchi Y, Utsumi M, Morita Y, Tsukui H, Terasawa M, Shibata T, Nishida K, Kobayashi Y, Petrich BG, Nakauchi H, Eto K, Okano T.

Blood. 2012 Jan 5;119(1):83-94. doi: 10.1182/blood-2011-02-335430. Epub 2011 Nov 16.

18.

Tumor necrosis factor restricts hematopoietic stem cell activity in mice: involvement of two distinct receptors.

Pronk CJ, Veiby OP, Bryder D, Jacobsen SE.

J Exp Med. 2011 Aug 1;208(8):1563-70. doi: 10.1084/jem.20110752. Epub 2011 Jul 18.

19.

Thrombopoietin and hematopoietic stem cells.

de Graaf CA, Metcalf D.

Cell Cycle. 2011 May 15;10(10):1582-9. Epub 2011 May 15. Review.

20.

Regulation of hematopoietic stem cells by their mature progeny.

de Graaf CA, Kauppi M, Baldwin T, Hyland CD, Metcalf D, Willson TA, Carpinelli MR, Smyth GK, Alexander WS, Hilton DJ.

Proc Natl Acad Sci U S A. 2010 Dec 14;107(50):21689-94. doi: 10.1073/pnas.1016166108. Epub 2010 Nov 29.

Supplemental Content

Support Center